# The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct06408532` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06408532](<https://clinicaltrials.gov/study/NCT06408532>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06408532

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 256 participants.

## Technical summary

Registry record NCT06408532. Randomized; single masking; primary purpose treatment. Start 2024-04-30 (anticipated); primary completion 2024-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 256 participants (planned count; ClinicalTrials.gov record NCT06408532, source copy `cardio:ctgov-nct06408532-2024-05-10`, retrieved 2026-10-26)
- Planned start: 2024-04-30 (anticipated) (ClinicalTrials.gov record NCT06408532, source copy `cardio:ctgov-nct06408532-2024-05-10`, retrieved 2026-10-26)
- Primary completion: 2024-10-30 (anticipated) (ClinicalTrials.gov record NCT06408532, source copy `cardio:ctgov-nct06408532-2024-05-10`, retrieved 2026-10-26)
- Completion: 2025-02-28 (anticipated) (ClinicalTrials.gov record NCT06408532, source copy `cardio:ctgov-nct06408532-2024-05-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06408532-2024-05-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): IDegLira
- Intervention (Drug): Premixed insulin
- Lead sponsor: Peking University People's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Peking University People's Hospital (`cardio:org-peking-university-people-s-hospital`)

## Provenance

Content hash: 56418c47d2ae3e49f05f1032320b01d210bef0465938d262615d8523d6bfc3a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
